Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $109.1 million.

  • Apellis Pharmaceuticals' Net Cash Flow rose 197.81% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.3 million, marking a year-over-year increase of 246.50%. This contributed to the annual value of $61.0 million for FY2024, which is 130.35% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Net Cash Flow stood at $109.1 million, which was up 896.10% from $11.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Net Cash Flow ranged from a high of $356.4 million in Q4 2021 and a low of -$298.4 million during Q1 2021.
  • Moreover, its 3-year median value for Net Cash Flow was $11.0 million (2025), whereas its average is -$6.6 million.
  • Over the last 5 years, Apellis Pharmaceuticals' Net Cash Flow had its largest YoY gain of 3,233.39% in 2023, and its largest YoY loss of 717.05% in 2023.
  • Apellis Pharmaceuticals' Net Cash Flow (Quarterly) stood at $356.4 million in 2021, then tumbled by 109.14% to -$32.6 million in 2022, then slumped by 212.59% to -$101.8 million in 2023, then skyrocketed by 115.07% to $15.3 million in 2024, then surged by 197.81% to $109.1 million in 2025.
  • Its Net Cash Flow stands at $109.1 million for Q3 2025, versus $11.0 million for Q2 2025 and -$53.1 million for Q1 2025.